Literature DB >> 17891260

Clinical aspects of super-refractory schizophrenia: a 6-month cohort observational study.

Jorge Henna Neto1, Hélio Elkis.   

Abstract

OBJECTIVE: Approximately 30% of treatment-resistant schizophrenic patients do not fully respond to Clozapine and such patients are termed Clozapine non-responders or super-refractory schizophrenics. The aim of this study was to characterize patients with super-refractory schizophrenia according to demographic and psychopathological variables, as compared with patients with refractory schizophrenia or non-refractory subjects.
METHOD: One hundred two outpatients meeting DSM-IV criteria for schizophrenia were followed-up for 6 months. Subjects were classified into 3 groups: non-refractory (n=25), refractory (n=43) and super-refractory (n=34). Psychopathology was assessed by the Positive and Negative Syndrome Scale, the Schedule for Deficit Syndrome, the Calgary Depression Scale and the Quality of Life Scale. Patients were rated at 2-month intervals.
RESULTS: Higher levels of severity at the disease onset as well as higher severity of positive symptoms were found to be predictive of super-refractoriness.
CONCLUSIONS: The super-refractory schizophrenia patients have psychopathological predictive factors that need studies comparing brain images, genetical features and other clinical comparisons.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17891260     DOI: 10.1590/s1516-44462007000300007

Source DB:  PubMed          Journal:  Braz J Psychiatry        ISSN: 1516-4446            Impact factor:   2.697


  4 in total

1.  Machine Learning Algorithm-Based Prediction Model for the Augmented Use of Clozapine with Electroconvulsive Therapy in Patients with Schizophrenia.

Authors:  Hong Seok Oh; Bong Ju Lee; Yu Sang Lee; Ok-Jin Jang; Yukako Nakagami; Toshiya Inada; Takahiro A Kato; Shigenobu Kanba; Mian-Yoon Chong; Sih-Ku Lin; Tianmei Si; Yu-Tao Xiang; Ajit Avasthi; Sandeep Grover; Roy Abraham Kallivayalil; Pornjira Pariwatcharakul; Kok Yoon Chee; Andi J Tanra; Golam Rabbani; Afzal Javed; Samudra Kathiarachchi; Win Aung Myint; Tran Van Cuong; Yuxi Wang; Kang Sim; Norman Sartorius; Chay-Hoon Tan; Naotaka Shinfuku; Yong Chon Park; Seon-Cheol Park
Journal:  J Pers Med       Date:  2022-06-14

2.  Place of the partial dopamine receptor agonist aripiprazole in the management of schizophrenia in adults: a Delphi consensus study.

Authors:  Pierre-Michel Llorca; Philippe Nuss; Éric Fakra; Isabelle Alamome; Dominique Drapier; Wissam El Hage; Renaud Jardri; Stéphane Mouchabac; Marc Rabbani; Nicolas Simon; Marie-Noëlle Vacheron; Jean-Michel Azorin
Journal:  BMC Psychiatry       Date:  2022-05-28       Impact factor: 4.144

3.  A false case of clozapine-resistant schizophrenia.

Authors:  J P Maia-de-Oliveira; J P Pinto; V Alexandre; J P Machado-de-Sousa; S L Morais; C Chaves; A C Sakamoto; A W Zuardi; J A S Crippa; J E Hallak
Journal:  Case Rep Med       Date:  2010-03-11

4.  The CYP2C19*2 and CYP2C19*17 Polymorphisms Influence Responses to Clozapine for the Treatment of Schizophrenia.

Authors:  Christielly Rodrigues-Silva; Agostinho Tavares Semedo; Hiasmin Franciely da Silva Neri; Rosana Pereira Vianello; Carlos Galaviz-Hernández; Martha Sosa-Macías; Rodrigo Bernini de Brito; Paulo César Ghedini
Journal:  Neuropsychiatr Dis Treat       Date:  2020-02-11       Impact factor: 2.570

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.